Annals of Oncology

in this issue
pp. 1033-1033(1)

Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?
pp. 1035-1036(2)
Author: Pritchard, K. I.

Predicting survival in advanced cancer patients: is it possible with patient-reported health status data?
pp. 1037-1038(2)
Authors: Bottomley, A.; Efficace, F.

Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005
pp. 1039-1050(12)
Authors: Pelucchi, C.; Pira, E.; Piolatto, G.; Coggiola, M.; Carta, P.; La Vecchia, C.

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO)
pp. 1051-1059(9)
Authors: Sandherr, M.; Einsele, H.; Hebart, H.; Kahl, C.; Kern, W.; Kiehl, M.; Massenkeil, G.; Penack, O.; Schiel, X.; Schuettrumpf, S.; Ullmann, A. J.; Cornely, O. A.

Introduction: ASCO-ESMO consensus statement on quality cancer care
pp. 1061-1061(1)
Authors: Horning, S. J.; Mellstedt, H.

ASCO-ESMO consensus statement on quality cancer care
pp. 1063-1064(2)

Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
pp. 1065-1071(7)
Authors: Veronesi, U.; Mariani, L.; Decensi, A.; Formelli, F.; Camerini, T.; Miceli, R.; Di Mauro, M. G.; Costa, A.; Marubini, E.; Sporn, M. B.; De Palo, G.

Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases
pp. 1072-1082(11)
Authors: Botteman, M.; Barghout, V.; Stephens, J.; Hay, J.; Brandman, J.; Aapro, M.

Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma
pp. 1083-1089(7)
Authors: Yeo, W.; Mo, F. K. F.; Koh, J.; Chan, A. T. C.; Leung, T.; Hui, P.; Chan, L.; Tang, A.; Lee, J. J.; Mok, T. S. K.; Lai, P. B. S.; Johnson, P. J.; Zee, B.

Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing
pp. 1090-1095(6)
Authors: van Oostrom, I.; Meijers-Heijboer, H.; Duivenvoorden, H. J.; Bröcker-Vriends, A. H. J. T.; van Asperen, C. J.; Sijmons, R. H.; Seynaeve, C.; Van Gool, A. R.; Klijn, J. G. M.; Tibben, A.

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
pp. 1096-1102(7)
Authors: Richards, D. A.; Boehm, K. A.; Waterhouse, D. M.; Wagener, D. J.; Krishnamurthi, S. S.; Rosemurgy, A.; Grove, W.; Macdonald, K.; Gulyas, S.; Clark, M.; Dasse, K. D.

Improved incidence of pT₀ downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation
pp. 1103-1110(8)
Authors: Calvo, F. A.; Serrano, F. J.; Diaz-González, J. A.; Gomez-Espi, M.; Lozano, E.; Garcia, R.; de la Mata, D.; Arranz, J. A.; García-Alfonso, P.; Pérez-Manga, G.; Álvarez, E.

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
pp. 1111-1119(9)
Authors: Booton, R.; Lorigan, P.; Anderson, H.; Baka, S.; Ashcroft, L.; Nicolson, M.; O'Brien, M.; Dunlop, D.; O'Byrne, K.; Laurence, V.; Snee, M.; Dark, G.; Thatcher, N.

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
pp. 1120-1127(8)
Authors: Cappuzzo, F.; Toschi, L.; Tallini, G.; Ceresoli, G. L.; Domenichini, I.; Bartolini, S.; Finocchiaro, G.; Magrini, E.; Metro, G.; Cancellieri, A.; Trisolini, R.; Crino, L.; Bunn, P. A.; Santoro, A.; Franklin, W. A.; Varella-Garcia, M.; Hirsch, F. R.

A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer
pp. 1128-1133(6)
Authors: Soo, R. A.; Wang, L. Z.; Tham, L. S.; Yong, W. P.; Boyer, M.; Lim, H. L.; Lee, H. S.; Millward, M.; Liang, S.; Beale, P.; Lee, S. C.; Goh, B. C.

Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
pp. 1134-1140(7)
Authors: Barkholt, L.; Bregni, M.; Remberger, M.; Blaise, D.; Peccatori, J.; Massenkeil, G.; Pedrazzoli, P.; Zambelli, A.; Bay, J.-O.; Francois, S.; Martino, R.; Bengala, C.; Brune, M.; Lenhoff, S.; Porcellini, A.; Falda, M.; Siena, S.; Demirer, T.; Niederwieser, D.; On behalf of the French ITAC group and the EBMT Solid Tumour Working Party,

Prospective trial on topotecan salvage therapy in primary CNS lymphoma
pp. 1141-1145(5)
Authors: Fischer, L.; Thiel, E.; Klasen, H.-A.; Birkmann, J.; Jahnke, K.; Martus, P.; Korfel, A.

An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients
pp. 1146-1151(6)
Authors: Palmieri, S.; D'Arco, A. M.; Celentano, M.; Mele, G.; Califano, C.; Pollio, F.; D'Amico, M. R.; Ferrara, F.

Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma
pp. 1152-1157(6)
Authors: Wong, A. S. C.; Soo, R. A.; Lu, J. J.; Loh, K. S.; Tan, K. S.; Hsieh, W. S.; Shakespeare, T. P.; Chua, E. T.; Lim, H. L.; Goh, B. C.

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
pp. 1158-1165(8)
Authors: Dumez, H.; Awada, A.; Piccart, M.; Assadourian, S.; Semiond, D.; Guetens, G.; de Boeck, G.; Maes, R. A. A.; de Bruijn, E. A.; van Oosterom, A.

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran
pp. 1166-1171(6)
Author: Safarinejad, M. R.

Reply to Letter to the Editor `Weekly oxaliplatin and pre-operative radiotherapy as a new neoadjuvant therapy for locally advanced rectal cancer', by T. Watanabe et al. (Ann Oncol 2006; 17: 1173)
pp. 1173-1174(2)
Authors: Aschele, C.; Friso, M. L.; Del Bianco, P.; Pucciarelli, S.

Weekly oxaliplatin and preoperative radiotherapy as a new neoadjuvant therapy for locally-advanced rectal cancer
pp. 1173-1173(1)
Authors: Watanabe, T.; Kiyomatsu, T.; Kanazawa, T.; Kazama, Y.; Kojima, T.; Tanaka, J.; Tanaka, T.; Nagawa, H.

Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy
pp. 1174-1175(2)
Authors: Curigliano, G.; Formica, V.; De Pas, T.; Spitaleri, G.; Pietri, E.; Fazio, N.; de Braud, F.; Goldhirsch, A.

Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?
pp. 1175-1176(2)
Authors: Yoneda, K.; Tanji, Y.; Okishiro, M.; Taguchi, T.; Tamaki, Y.; Noguchi, S.

Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients
pp. 1176-1177(2)
Authors: Berretta, M.; Lleshi, A.; Di Benedetto, F.; Bearz, A.; Spina, M.; Tirelli, U.

Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event
pp. 1177-1178(2)
Authors: Roncalli, J.; Delord, J. P.; Galinier, M.; Massabuau, P.; Lescure, M.; Fauvel, J. M.; Azria, D.